Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Primary Purpose
Obesity, Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Laboratory evaluations, sleep study
Best Medical Management
Roux-en-Y gastric bypass surgery
Sponsored by

About this trial
This is an interventional diagnostic trial for Obesity focused on measuring Obesity, Type 2 Diabetes Mellitus, Roux-en-Y Gastric Bypass Surgery
Eligibility Criteria
Inclusion Criteria:
- Age 25 to 70
- BMI 35 or greater
- HbA1c>6.5%
- Stable weight
- Stable medications
Exclusion Criteria:
- Coagulopathy
- Liver cirrhosis
- C-peptide <1 ng/ml (off insulin)
- Diagnosis of severe eating disorder
- Untreated endocrine disorder
- Use of medication for weight loss in the past 6 months
- Use of medication for weight loss in the last 6 months (with the exception of orlistat)
- Pregnancy
- Coagulopathy
- Liver cirrhosis
- Incurable, malignant, or debilitating disease
- Severe eating disorder
- Use of weight loss medication in the last 6 months, with the exception of orlistat
- Untreated endocrine disorder
- Pregnant
- Inability to provide informed consent
Sites / Locations
- The Ohio State University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Best Medical Management
Surgical Treatment
Arm Description
Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
Outcomes
Primary Outcome Measures
Resolution of type 2 diabetes mellitus, determined by oral glucose tolerance test.
Resolution of obesity co-morbidities including hypertension, OSA, and hyperlipidemia
Secondary Outcome Measures
Improvement in glucose control
Improvement in control of chronic co-morbidities
Identify predictors of success with regard to improved co-morbidities and velocity of weight loss
Full Information
NCT ID
NCT01044602
First Posted
January 7, 2010
Last Updated
April 20, 2015
Sponsor
David Bradley MD
Collaborators
Medtronic - MITG
1. Study Identification
Unique Protocol Identification Number
NCT01044602
Brief Title
Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Official Title
Metabolic Surgery vs. Medical Management for Resolution of Type II Diabetes: A Prospective Group Match Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
David Bradley MD
Collaborators
Medtronic - MITG
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Best medical management and gastric bypass surgery is a way to treat diabetes as part of regular medical care (standard of care). However, gastric bypass surgery is not a way to treat diabetes as part of regular medical care (standard of care).
Detailed Description
Best medical management and gastric bypass surgery are ways to treat obesity as part of regular medical care (standard of care). Best medical management is a way to treat diabetes as part of regular medical care (standard of care). However, gastric bypass surgery is not a way to treat diabetes as part of regular medical care (standard of care). But, studies suggest that diabetes gets better or goes away after gastric bypass surgery. This study is being done to find out if diabetes gets better or goes away completely after a patient has gastric bypass surgery as part of regular medical care (standard of care).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Type 2 Diabetes Mellitus
Keywords
Obesity, Type 2 Diabetes Mellitus, Roux-en-Y Gastric Bypass Surgery
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Best Medical Management
Arm Type
Active Comparator
Arm Description
Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
Arm Title
Surgical Treatment
Arm Type
Active Comparator
Arm Description
Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
Intervention Type
Other
Intervention Name(s)
Laboratory evaluations, sleep study
Intervention Description
Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
Intervention Type
Other
Intervention Name(s)
Best Medical Management
Intervention Description
Standard of care.
Intervention Type
Procedure
Intervention Name(s)
Roux-en-Y gastric bypass surgery
Intervention Description
Surgical treatment.
Primary Outcome Measure Information:
Title
Resolution of type 2 diabetes mellitus, determined by oral glucose tolerance test.
Time Frame
2 years
Title
Resolution of obesity co-morbidities including hypertension, OSA, and hyperlipidemia
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Improvement in glucose control
Time Frame
2 years
Title
Improvement in control of chronic co-morbidities
Time Frame
2 years
Title
Identify predictors of success with regard to improved co-morbidities and velocity of weight loss
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 25 to 70
BMI 35 or greater
HbA1c>6.5%
Stable weight
Stable medications
Exclusion Criteria:
Coagulopathy
Liver cirrhosis
C-peptide <1 ng/ml (off insulin)
Diagnosis of severe eating disorder
Untreated endocrine disorder
Use of medication for weight loss in the past 6 months
Use of medication for weight loss in the last 6 months (with the exception of orlistat)
Pregnancy
Coagulopathy
Liver cirrhosis
Incurable, malignant, or debilitating disease
Severe eating disorder
Use of weight loss medication in the last 6 months, with the exception of orlistat
Untreated endocrine disorder
Pregnant
Inability to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Asem Ali, MD
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Ohio State University Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
We'll reach out to this number within 24 hrs